Cue Biopharma Stock Forecast
NASDAQ: CUEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 1:32 PM ET
CUE analyst consensus
Consensus (3 analysts)
strong_buy
Avg. price target
$88.00+292.51%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering Cue Biopharma (2026-10-08), 3 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $88.00, with a high estimate of $115.00 and a low estimate of $66.00. The average target implies upside of 292.5% from the current price of $22.42.
The spread between the highest and lowest targets is 74.2%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CUE.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $66.00 | +194.38% |
| Average target | $88.00 | +292.51% |
| High target | $115.00 | +412.93% |